Mustang’s lead CAR T cell program, MB-106, is a third-generation CAR T cell therapy with a fully human target-binding domain for the treatment of NHL and CLL. MB-106 targets CD20, a clinically ...

This study provides a valuable new resource to investigate the molecular basis of the particular features characterizing the pipefish embryo. The authors found both unique and shared gene expression ...

However, traditional CAR T cell therapy has had limited success in solid tumors. Shipra Das, an immunooncologist at Cellectis, discussed a novel approach using transcription activation-like effector ...